Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
Image
Date de parution
2024/04/02
PDF du document
Crossject_PR_FinResults_EN_0.pdf
253.02 KB
